Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant trastuzumab emtansine versus trastuzumab in HER2-positive breast cancer with residual disease after neoadjuvant therapy
2012-002018-37Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Started Feb 2013; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002018-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002018-37.